Genesis Research halted from trading pending statement

Genesis Research and Development, which in July abandoned plans to merge with an unlisted Australian company, had its shares halted from trading pending an announcement.

The company suspended operations in May 2010 and laid off its entire staff. In July this year it placed 9.1 million shares, which it said gave it enough funds to remain listed while it considers further investments.

The shares last traded at 1.8 cents, valuing the company at $980,000, and have declined 40 percent in the past year.

In July, Genesis called off a proposed merger with Australia-based Mariposa Health, an unlisted public pharmaceutical development company.

BusinessDesk.co.nz

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

Genesis Research directors quit due to lack of funds & communication
Genesis Research has ‘lack of funds’, seeks legal advice on future
Genesis Research calls off proposed merger with Mariposa Health
Kupe earnings bolster Genesis 1H profit by 125%
Genesis Research plans "reverse takeover"
Genesis Research director Graham Chin resigns in wake of rift with UBNZ
Tekapo purchase knocks $73m off Genesis bottom line
UBNZ gets in deeper with Genesis Research
Genesis Energy beats forecast
Genesis forecasts profit jump